Evidence map›Paper›PMID 40027916›Full record

ReviewInfection and drug resistance2025

Type II Toxin-Antitoxin Systems in

He Zhang, Shuan Tao, Huimin Chen, Yewei Fang, Yao Xu, A-Xiang Han, Fang Ma, Wei Liang

Abstract readReview
In one paragraph

Review in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

He ZhangDepartment of Medical Laboratory, Bengbu Medical University, Bengbu, Anhui, People's Republic of China.ORCID 0009-0004-3886-4952
Shuan TaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.ORCID 0000-0001-9813-8814
Huimin ChenDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Yewei FangDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.ORCID 0009-0009-3671-3292
Yao XuSchool of Medicine, Ningbo University, Ningbo, Zhejiang, People's Republic of China.
A-Xiang HanDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Fang Ma *Department of Medical Laboratory, Bengbu Medical University, Bengbu, Anhui, People's Republic of China.
Wei Liang *Department of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The toxin-antitoxin (TA) system is widespread in prokaryotes and archaea, comprising toxins and antitoxins that counterbalance each other. Based on the nature and mode of action of antitoxins, they are classified into eight groups (type I to VIII). Both the toxins and the antitoxins are proteins in type II TA systems, and the antitoxin gene is usually upstream of the toxin gene. Both genes are organized in an operon and expression of which is regulated at the transcriptional level by the antitoxin-toxin complex, which binds the operon DNA through the DNA-binding domain of the antitoxin. The TA system plays a crucial role in various cellular processes, such as programmed cell death, cell growth, persistence, and virulence. Currently, Type II TA systems have been used as a target for developing new antibacterial agents for treatment. Therefore, the focus of this review is to understand the unique response of Type II TA in

Indexed as

bacterial persistencebiofilm formationE. coliphage infectiontype II toxin-antitoxin

Identifiers

PMID40027916
PMCPMC11869752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.